Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 18,700 Shares

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 18,700 shares of the firm’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $77.84, for a total transaction of $1,455,608.00. Following the transaction, the insider directly owned 212,523 shares in the company, valued at approximately $16,542,790.32. The trade was a 8.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Carl Dambkowski also recently made the following trade(s):

• On Thursday, December 4th, Carl Dambkowski sold 10,900 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.00, for a total transaction of $817,500.00.
• On Wednesday, November 5th, Carl Dambkowski sold 10,785 shares of Apogee Therapeutics stock. The shares were sold at an average price of $55.07, for a total transaction of $593,929.95.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE opened at $77.99 on Friday. Apogee Therapeutics Inc. has a 12 month low of $26.20 and a 12 month high of $80.99. The stock has a market cap of $5.33 billion, a price-to-earnings ratio of -17.81 and a beta of 1.41. The stock’s 50 day moving average price is $70.89 and its 200 day moving average price is $51.85.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, November 10th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.03. On average, sell-side analysts expect that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP lifted its holdings in shares of Apogee Therapeutics by 24.1% in the third quarter. Wellington Management Group LLP now owns 4,723,701 shares of the company’s stock valued at $187,673,000 after purchasing an additional 917,991 shares in the last quarter. Vanguard Group Inc. raised its position in Apogee Therapeutics by 6.5% during the third quarter. Vanguard Group Inc. now owns 2,245,631 shares of the company’s stock valued at $89,219,000 after buying an additional 136,693 shares during the period. Paradigm Biocapital Advisors LP raised its position in Apogee Therapeutics by 58.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,521,757 shares of the company’s stock valued at $60,459,000 after buying an additional 563,127 shares during the period. Alliancebernstein L.P. lifted its stake in Apogee Therapeutics by 2.2% in the 3rd quarter. Alliancebernstein L.P. now owns 1,419,132 shares of the company’s stock worth $56,382,000 after acquiring an additional 30,983 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in Apogee Therapeutics by 77.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,290,464 shares of the company’s stock worth $56,045,000 after acquiring an additional 563,464 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Wall Street Analyst Weigh In

APGE has been the topic of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. BTIG Research set a $137.00 target price on shares of Apogee Therapeutics in a report on Tuesday. Royal Bank Of Canada restated an “outperform” rating on shares of Apogee Therapeutics in a report on Tuesday. Wall Street Zen cut Apogee Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Finally, Mizuho started coverage on Apogee Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $105.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.27.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.